Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells

The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from PD-1/PD-L1 blockade, largely because of immunosuppression. New immunotherapy-based combinations are under investigation in an attempt to improve outcomes. <...

Full description

Bibliographic Details
Main Authors: Iosune Baraibar, Marta Roman, María Rodríguez-Remírez, Inés López, Anna Vilalta, Elisabeth Guruceaga, Margarita Ecay, María Collantes, Teresa Lozano, Diego Alignani, Ander Puyalto, Ana Oliver, Sergio Ortiz-Espinosa, Haritz Moreno, María Torregrosa, Christian Rolfo, Christian Caglevic, David García-Ros, María Villalba-Esparza, Carlos De Andrea, Silvestre Vicent, Rubén Pío, Juan José Lasarte, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
KRAS lung adenocarcinoma
inhibitor of differentiation
PD-1 inhibition
PD-L1
Online Access:https://www.mdpi.com/2072-6694/12/11/3169

Internet

https://www.mdpi.com/2072-6694/12/11/3169

Similar Items